PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17047615-2 2006 Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia]. Atorvastatin 27-39 fibrinogen beta chain Homo sapiens 85-95 23654149-3 2012 Additional use of atorvastatin to a conventional therapy leads to significant reduction of C-reactive protein and fibrinogen and improves effect of long-term sinus rhythm maintenance. Atorvastatin 18-30 fibrinogen beta chain Homo sapiens 114-124 16916124-7 2006 Atorvastatin significantly increased the levels of fibrinogen (p < 0.001), but it had no effect on other coagulation factors and homocysteine (p > 0.05). Atorvastatin 0-12 fibrinogen beta chain Homo sapiens 51-61 18000162-3 2008 OBJECTIVE: To evaluate the efficacy of atorvastatin compared with a control group in inducing changes in lipoprotein(a) [Lp(a)], apolipoprotein (Apo) A-1, Apo-B, and fibrinogen levels, as well as the conventional lipoprotein profile, in hemodialysis patients over 36 weeks; secondary objectives were to assess changes in C-reactive protein, albumin, and safety measures. Atorvastatin 39-51 fibrinogen beta chain Homo sapiens 166-176 12659599-13 2003 Moreover, fibrinogen levels decreased with simvastatin and atorvastatin, but these reductions were significant only for simvastatin (p < 0.05). Atorvastatin 59-71 fibrinogen beta chain Homo sapiens 10-20 15598024-2 2004 The aim of this study was to assess the effect of 30-day atorvastatin treatment on major hemostatic risk factors (fibrinogen, PAI-1 levels, factor VII coagulant activity) in patients with primary hypercholesterolemia. Atorvastatin 57-69 fibrinogen beta chain Homo sapiens 114-124 15598024-5 2004 Atorvastatin (20 mg/d) not only decreased total cholesterol, LDL cholesterol and oxidized LDL, but also reduced PAI-1 levels and factor VII activity and tended to decrease fibrinogen levels. Atorvastatin 0-12 fibrinogen beta chain Homo sapiens 172-182 15326822-0 2004 Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the anti-inflammatory effects of statins. Atorvastatin 0-12 fibrinogen beta chain Homo sapiens 21-31 15326822-3 2004 OBJECTIVES: To evaluate the effect of atorvastatin on plasma fibrinogen levels in patients with severe hypercholesterolemia and no other risk factors. Atorvastatin 38-50 fibrinogen beta chain Homo sapiens 61-71 15326822-12 2004 CONCLUSIONS: We found that atorvastatin reduces plasma fibrinogen in patients with hypercholesterolemia. Atorvastatin 27-39 fibrinogen beta chain Homo sapiens 55-65 12615272-0 2003 Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia. Atorvastatin 10-22 fibrinogen beta chain Homo sapiens 65-75 12127376-9 2002 CONCLUSIONS: These results suggest that lipid lowering with atorvastatin therapy significantly increases GFC, decreases fibrinogen levels, and causes leukocyte deactivation. Atorvastatin 60-72 fibrinogen beta chain Homo sapiens 120-130 11254918-2 2001 In this randomized placebo-controlled crossover study, we evaluated whether changes in fibrinogen levels were different between atorvastatin and other statin-treated patients. Atorvastatin 128-140 fibrinogen beta chain Homo sapiens 87-97 10910028-3 2000 However, conflicting data have been published concerning the effect of atorvastatin on fibrinogen concentration. Atorvastatin 71-83 fibrinogen beta chain Homo sapiens 87-97 11215845-7 2001 Atorvastatin has been shown to induce significant increases in fibrinogen (22% increase; p <0.05) by using the immunonephelometric method. Atorvastatin 0-12 fibrinogen beta chain Homo sapiens 63-73 11165973-2 2001 Hyperfibrinogenemia was associated with atorvastatin, baseline fibrinogen, and initial concentration and change in concentration of apolipoprotein B or low-density lipoprotein cholesterol. Atorvastatin 40-52 fibrinogen beta chain Homo sapiens 5-15 11215845-6 2001 The effects of four HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin, pravastatin) on fibrinogen have been evaluated. Atorvastatin 50-62 fibrinogen beta chain Homo sapiens 105-115 11268711-7 2001 A small non-significant increase of plasma fibrinogen was found (3.04 g/l vs. 3.14 g/l) after 24 weeks of atorvastatin administration. Atorvastatin 106-118 fibrinogen beta chain Homo sapiens 43-53 9492781-0 1998 Effect of atorvastatin on plasma fibrinogen. Atorvastatin 10-22 fibrinogen beta chain Homo sapiens 33-43 11078305-8 2000 Thus, atorvastatin 80 mg/day produced marked reductions in serum low-density lipoprotein cholesterol (-53%), very low density lipoprotein cholesterol (-43%), and triglycerides levels (-35%), and significant changes in plasma viscosity as well as other hemorheologic-hemostatic parameters, but no changes in plasma fibrinogen levels. Atorvastatin 6-18 fibrinogen beta chain Homo sapiens 314-324 10644290-0 2000 More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia. Atorvastatin 22-34 fibrinogen beta chain Homo sapiens 45-55 10217377-0 1999 More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atorvastatin 22-34 fibrinogen beta chain Homo sapiens 45-55 11563401-9 1999 Simvastatin has no effect on platelet-thrombus formation or fibrinogen levels, while atorvastatin and lovastatin have been shown to increase fibrinogen in some studies. Atorvastatin 85-97 fibrinogen beta chain Homo sapiens 141-151 32696349-6 2021 In group 2, atorvastatin exerted also a more potent impact on hsCRP, fibrinogen and homocysteine. Atorvastatin 12-24 fibrinogen beta chain Homo sapiens 69-79 18370543-12 1998 CONCLUSIONS: Atorvastatin in equipotent doses to simvastatin appeared to be more effective than the latter in reducing triglyceride and plasma fibrinogen in patients with hypercholesterolaemia, mainly in those with Frederickson"s phenotype Iib. Atorvastatin 13-25 fibrinogen beta chain Homo sapiens 143-153 33826536-8 2021 In groups B and C, atorvastatin use was also associated with a decrease in uric acid, fibrinogen and homocysteine concentrations and with an increase in 25-hydroxyvitamin D levels. Atorvastatin 19-31 fibrinogen beta chain Homo sapiens 86-96 26721373-9 2016 Apart from an increase in testosterone levels, if administered to atorvastatin-treated subjects with LOH, testosterone reduced plasma levels of LDL cholesterol, uric acid, hsCRP, homocysteine, and fibrinogen, as well as improved insulin sensitivity. Atorvastatin 66-78 fibrinogen beta chain Homo sapiens 197-207 31409451-8 2019 In normoprolactinemic women, atorvastatin decreased circulating levels of uric acid, hsCRP, fibrinogen, homocysteine, and increased concentrations of 25-hydroxyvitamin D, whereas in women with macroprolactinemia the drug decreased levels of hsCRP and homocysteine, as well as impaired insulin sensitivity. Atorvastatin 29-41 fibrinogen beta chain Homo sapiens 92-102 28804682-9 2017 For the inflammatory biomarkers at 24 hours after PCI, the fibrinogen level was significantly increased in the atorvastatin group; the hs-CRP levels were significantly increased in both groups, however, the hs-CRP level in the pitavastatin group was lower than that in the atorvastatin group. Atorvastatin 111-123 fibrinogen beta chain Homo sapiens 59-69 27717074-8 2016 Although atorvastatin decreased plasma levels of total cholesterol and LDL-C to a similar extent in all study groups, its effect on uric acid, hsCRP, homocysteine, and fibrinogen was more pronounced in patients from groups B and C than in men from group A. Atorvastatin 9-21 fibrinogen beta chain Homo sapiens 168-178